Amgen

Amgen[edit | edit source]

Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology firms, Amgen was established in 1980 and has since led the industry in the development of novel therapies to treat serious illnesses.

History[edit | edit source]

Amgen was founded by George B. Rathmann, a former chemist at 3M, with the goal of harnessing the power of genetic engineering to produce human proteins for therapeutic uses. The company's name, "Amgen", is a portmanteau of the words "applied molecular genetics".

Products and Therapies[edit | edit source]

Amgen's product portfolio includes a wide range of innovative medicines that have transformed the treatment landscape for patients suffering from serious diseases such as cancer, kidney disease, rheumatoid arthritis, and osteoporosis. Some of the company's most notable products include:

Epogen: A recombinant form of human erythropoietin used to treat anemia associated with chronic kidney disease.
Neulasta: A long-acting form of granulocyte colony-stimulating factor used to reduce the risk of infection in patients undergoing chemotherapy.
Prolia: A human monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture.

Research and Development[edit | edit source]

Amgen's research and development efforts are focused on leveraging its expertise in biotechnology to discover and develop innovative therapies for patients with serious illnesses. The company's R&D activities span a wide range of therapeutic areas, including oncology, cardiovascular disease, inflammation, bone health, and neuroscience.

Corporate Responsibility[edit | edit source]

Amgen is committed to corporate responsibility and strives to make a positive impact on society through its business practices, philanthropic activities, and commitment to environmental sustainability.